PD-1 ⁺ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer

Takahiro Kamada, Yosuke Togashi, Christopher Tay, +13

Proceedings of the National Academy of Sciences

Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603)

Shota Fukuoka, Hiroki Hara, Naoki Takahashi, +15

Journal of Clinical Oncology

The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies

Shogo Kumagai, Yosuke Togashi, Takahiro Kamada, +28

Nature Immunology

Cancer ImmunosurveillanceAutoimmune DiseaseT-regulatory CellPd-1 Expression BalanceClinical Efficacy +10

Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments

Shogo Kumagai, Shohei Koyama, Kota Itahashi, +43

Cancer Cell

Cancer ImmunosurveillancePd-1 ExpressionMedicineT-regulatory CellImmunology +9

The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer

Yelena Y. Janjigian, Akihito Kawazoe, Patricio Yañez, +16

Nature

Gastrointestinal OncologyMedicineHer2 BlockadeImmunologyGastroenterology +7

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial

Sun Young Rha, Do‐Youn Oh, Patricio Yañez, +219

The Lancet Oncology

Chemotherapy Versus PlaceboGastrointestinal OncologyMedicineClinical TrialsImmune Checkpoint Inhibitor +6

Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial

Yelena Y. Janjigian, Akihito Kawazoe, Yuxian Bai, +17

The Lancet

Her2-positive GastricGastrointestinal OncologyInterim AnalysesMedicineGastroenterology +5

Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial

Akihito Kawazoe, Shota Fukuoka, Yoshiaki Nakamura, +10

The Lancet Oncology

Gastrointestinal OncologyAdvanced Gastric CancerMedicinePharmacologyGastroenterology +6

An Oncogenic Alteration Creates a Microenvironment that Promotes Tumor Progression by Conferring a Metabolic Advantage to Regulatory T Cells

Shogo Kumagai, Yosuke Togashi, Chika Sakai, +12

Immunity

Cancer ImmunosurveillanceOncogenic AlterationOncogenic AgentMedicineT-regulatory Cell +9

Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein–Barr virus status in a large cohort of gastric cancer patients

Akihito Kawazoe, Takeshi Kuwata, Yasutoshi Kuboki, +7

Gastric Cancer

Tumor BiologyLymphoid NeoplasiaCancer ImmunosurveillanceGastrointestinal OncologyMedicine +9